RxDoctor Payments Data

Kimberly Mitcham

Family · Baxley, GANPI 1720451297

Payments from drug & device makers

$893in general payments, 2019–2025

Across 25 payments — averaging $35.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$337
  • Novo Nordisk$149
  • E.r. Squibb & Sons, L.L.C.$128
  • AstraZeneca$125
  • Paratek Pharmaceuticals, Inc.$71
  • AbbVie$29
  • plus $54 from 3 others

What the payments were for

  • Travel & lodging$16518%
  • Food & beverage$72882%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$893 in reported general payments places this provider in the 65th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$11,761
Medicare patients
114
Services billed
227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide31$34,910
OzempicSemaglutide19$25,667
EliquisApixaban17$13,420
Albuterol Sulfate HfaAlbuterol Sulfate22$684
Aripiprazole14$545
Gabapentin39$425
Levothyroxine Sodium44$395
Ropinirole Hcl24$379
Duloxetine Hcl13$360
Quetiapine Fumarate16$272
Omeprazole21$268
Pantoprazole Sodium44$264
Atorvastatin Calcium46$241
Lisinopril50$239
Metformin Hcl36$228

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$149$25,66719 claims
PfizerEliquis$18$13,42017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,258 family providers in Georgia.

Other family in Baxley

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →